Clear Cell Renal Cell Carcinoma

CHICAGO — Researchers were unable to identify a discrete genomic biomarker of PFS after second line of therapy to help guide first-line regimen selection for patients with advanced clear cell renal cell carcinoma, according to a poster presentation at ASCO Annual Meeting.

CHICAGO — In patients with metastatic non-clear cell renal cell carcinoma, a high systemic inflammatory state at baseline was associated with worse outcomes after treatment with atezolizumab and bevacizumab, according to a poster presented at ASCO Annual Meeting.

Adjuvant pembrolizumab appeared associated with a significant and clinically meaningful improvement in DFS vs. placebo among patients with clear cell renal carcinoma, according to results of the KEYNOTE-564 trial.

Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy.

First-line pembrolizumab plus axitinib extended survival among patients with advanced renal cell carcinoma, according to updated results of the randomized phase 3 KEYNOTE-426 study presented during the ASCO20 Virtual Scientific Program.

Phase 1 study to determine the safety and feasibility of using HERV-E TCR-transduced autologous T Cells in patients with metastatic clear-cell renal-cell carcinoma.